<DOC>
	<DOCNO>NCT02119897</DOCNO>
	<brief_summary>Oral mucositis ( OM ) painful potentially debilitate acute toxicity frequently affect child undergo hematopoietic cell transplantation ( HCT ) . As result intensive conditioning chemotherapy without total body irradiation , case allogeneic HCT , graft-versus-host disease ( GVHD ) prophylaxis , patient risk develop diffuse ulceration oral esophageal mucosa result pain suffering , increased utilization opioid analgesic , need intravenous total parenteral nutritional support . Patients universally report OM bad aspect HCT experience.A novel approach use large light-emitting diode array treat risk tissue extraoral approach , enable exposure oral , oropharyngeal , esophageal mucosa avoid need intraoral manipulation , require minimal patient cooperation . In research study , investigator assess feasibility provide extraorally deliver low level light therapy ( LLLT ) prevention OM child undergo myeloablative HCT .</brief_summary>
	<brief_title>Feasibility Study Low Level Light Therapy Prevention Oropharyngeal Mucositis Pediatric Transplants Patients</brief_title>
	<detailed_description>This open label , single treatment arm clinical pilot study . The study target enroll twelve evaluable patient OBJECTIVES : Primary - Determine feasibility provide extraoral LLLT prevention OM pediatric patient undergo HCT Secondary - Determine feasibility collect data use WHO Oral Toxicity Scale ChIMES pediatric patient undergo myeloablative HCT treat extraoral LLLT prevention OM - Evaluate safety tolerability extraoral LLLT prevention OM pediatric patient undergo myeloablative HCT</detailed_description>
	<mesh_term>Mucositis</mesh_term>
	<criteria>Scheduled undergo myeloablative conditioning follow autologous allogeneic hematopoietic cell transplantation Boston Children 's Hospital . 4 year age 25 year age . WHO Oral Toxicity score 0 baseline evaluation ( first day conditioning ) . Ability understand willingness sign write informed consent document ( patient age 18 applies parent/guardian ) Ability understand and/or willingness parent legally authorize representative sign write informed consent document . Treatment oral LLLT within 4 week HCT . Participants may receive agent intend prevention/management mucositis ( include palifermin ice chips/cryotherapy ) . WHO â‰¥1 baseline evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Oropharyngeal Mucositis</keyword>
	<keyword>Myeloablative Hematopoietic Cell Transplantation</keyword>
	<keyword>Low Level Light Therapy</keyword>
</DOC>